It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Clinical features and natural history of coronavirus disease 2019 (COVID-19) differ widely among different countries and during different phases of the pandemia. Here, we aimed to evaluate the case fatality rate (CFR) and to identify predictors of mortality in a cohort of COVID-19 patients admitted to three hospitals of Northern Italy between March 1 and April 28, 2020. All these patients had a confirmed diagnosis of SARS-CoV-2 infection by molecular methods. During the study period 504/1697 patients died; thus, overall CFR was 29.7%. We looked for predictors of mortality in a subgroup of 486 patients (239 males, 59%; median age 71 years) for whom sufficient clinical data were available at data cut-off. Among the demographic and clinical variables considered, age, a diagnosis of cancer, obesity and current smoking independently predicted mortality. When laboratory data were added to the model in a further subgroup of patients, age, the diagnosis of cancer, and the baseline PaO2/FiO2 ratio were identified as independent predictors of mortality. In conclusion, the CFR of hospitalized patients in Northern Italy during the ascending phase of the COVID-19 pandemic approached 30%. The identification of mortality predictors might contribute to better stratification of individual patient risk.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Università del Piemonte Orientale UPO, Department of Translational Medicine, Novara, Italy (GRID:grid.16563.37) (ISNI:0000000121663741); Azienda Ospedaliero Universitaria “Maggiore Della Carita”, Novara, Italy (GRID:grid.412824.9) (ISNI:0000 0004 1756 8161)
2 Università del Piemonte Orientale UPO, Department of Translational Medicine, Novara, Italy (GRID:grid.16563.37) (ISNI:0000000121663741)
3 Azienda Ospedaliera SS. Antonio E Biagio E Cesare Arrigo, Alessandria, Italy (GRID:grid.412824.9)
4 Azienda Ospedaliero Universitaria “Maggiore Della Carita”, Novara, Italy (GRID:grid.412824.9) (ISNI:0000 0004 1756 8161)
5 Università del Piemonte Orientale UPO, Department of Translational Medicine, Novara, Italy (GRID:grid.16563.37) (ISNI:0000000121663741); Presidio Ospedaliero S. Andrea, ASL VC, Vercelli, Italy (GRID:grid.16563.37)
6 Presidio Ospedaliero S. Andrea, ASL VC, Vercelli, Italy (GRID:grid.16563.37)
7 Presidio Ospedaliero S. Andrea, ASL VC, Vercelli, Italy (GRID:grid.412824.9)
8 Azienda Ospedaliera SS. Antonio E Biagio E Cesare Arrigo, Alessandria, Italy (GRID:grid.16563.37)